🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. XELJANZ 1 mg/mL oral solution, XELJANZ 1 mg/mL oral solution, XELJANZ 1 mg/mL oral solution, Tofacitinib citrate, Tofacitinib citrate, XELJANZ 1 mg/mL oral solution

    Pfizer Australia Pty Ltd

    Ulcerative Colitis (UC)

    phase 3 small molecule active

    1 trial

  2. XEN1101

    Xenon Pharmaceuticals

    Focal Onset Seizures

    phase 3 small molecule active

    2 trials

  3. XEN1101

    Xenon Pharmaceuticals

    Focal Epilepsy

    phase 3 small molecule active

    2 trials

  4. XEN1101

    Xenon Pharmaceuticals

    Primary Generalized Tonic-Clonic Seizures

    phase 3 small molecule active

    1 trial

  5. XEOMIN 100 unités, poudre pour solution injectable

    Pari Pharma GmbH

    PANCREATIC FISTULA

    phase 3 small molecule active

    1 trial

  6. XEOMIN 200 V pulveris injekciju šķīduma pagatavošanai, Placebo to NT201, XEOMIN, 200 jednostek, proszek do sporządzania roztworu do wstrzykiwań

    Merz Pharmaceuticals GmbH

    Pediatric lower limb (LL) spasticity (SP) caused by cerebral palsy (CP)

    phase 3 small molecule active

    1 trial

  7. XEOMIN 200 jednotek prášek pro injekční roztok, XEOMIN, 200 jednostek, proszek do sporządzania roztworu do wstrzykiwań, XEOMEEN 200 eenheden poeder voor oplossing voor injectie, XEOMIN 200 egység por oldatos injekcióhoz, XEOMIN 200 jednotiek prášok na injekčný roztok, XEOMIN 200 unidades polvo para solución inyectable, XEOMEEN 200 unités poudre pour solution injectable, XEOMIN 200 Einheiten Pulver zur Herstellung einer Injektionslösung, XEOMIN 200 unités, poudre pour solution injectable, XEOMIN, 200 unità,

    Merz Pharmaceuticals GmbH

    Lower limb spasticity

    phase 3 small molecule active

    1 trial

  8. XEOMIN 200 unités, poudre pour solution injectable, Placebo of Xeomin 200 U

    Pari Pharma GmbH

    Adult patients with indication for conventional cardiac surgery (CABG, aortic replacement, or ascending aorta surgery)

    phase 3 small molecule active

    1 trial

  9. XPF-010

    Xenon Pharmaceuticals

    Depressive episodes associated with Bipolar disorder I or II (Bipolar Depression)

    phase 3 small molecule active

    1 trial

  10. XPF-010, Placebo to match XPF-010

    Xenon Pharmaceuticals

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  11. Xevinapant (Debio 1143)

    Serono Europe Limited

    Squamous Cell Carcinoma of the Head and Neck

    phase 3 small molecule terminated

    1 trial

  12. Xofigo 1100 kBq/mL solution for injection

    Ningbo Cancer Hospital

    metastatic Castration-Resistant Prostate Cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  13. Xolair 150 mg solution for injection in pre-filled syringe, Placebo, solution for injection in pre-filled syringe, BP11

    CuraTeQ Biologics s.r.o

    Chronic Urticaria

    phase 3 small molecule active

    1 trial

  14. Xtandi - 40 mg soft capsules, Flutamide 250 mg Tablets, Casodex® 50 mg Film-coated Tablets

    Ningbo Cancer Hospital

    Metastatic Prostate Cancer

    phase 3 small molecule active

    1 trial

  15. Xtandi - 40 mg soft capsules, PF-06821497, PF-06821497, Tablet to match placebo for pf-06821497 125mg, Tablet to match placebo for pf-06821497 250mg

    Pfizer Australia Pty Ltd

    METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER

    phase 3 small molecule active

    1 trial

  16. Xtandi - 40 mg soft capsules, Xofigo 1100 kBq/mL solution for injection

    Ningbo Cancer Hospital

    Castration resistant prostate cancer patients metastatic to bone.

    phase 3 small molecule active

    1 trial

  17. Xtandi - 40 mg soft capsules, Xtandi - 40 mg soft capsules, TALAZOPARIB, Xtandi 40 mg soft capsules, TALAZOPARIB, Xtandi - 40 mg soft capsules, Talazoparib placebo

    Pfizer Australia Pty Ltd

    Metastatic Castration-sensitive Prostate Cancer

    phase 3 small molecule active

    1 trial

  18. Xylocore Medium Strength, bicaVera 4,25 % Glucose, 1,75 mmol/l Calcium, Peritonealdialyselösung, Xylocore High Strength, PHYSIONEAL 40 Glucose 3,86 % w/v / 38,6 mg/ml, Peritonealdialyselösung, balance 4,25% Glucose, 1,75 mmol/l Calcium, Peritonealdialyselösung, PHYSIONEAL 35 Glucose 1,36 % w/v / 13,6 mg/ml, Peritonealdialyselösung, FIXIONEAL “35 Glucosio 3,86% p/v/38,6 mg/ml” in sacca Clear-Flex Soluzione per dialisi peritoneale, balance 2,3% Glucose, 1,75 mmol/l Calcium, Peritonealdialyselösung, PHYSIONEAL

    Lacuna Pharma Pty Ltd

    End-Stage Kidney Disease

    phase 3 small molecule active

    1 trial

  19. YAZ (SH T00186, BAY86-5300)

    Bayer HealthCare AG

    Contraception

    phase 3 small molecule completed

    1 trial

  20. YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion.

    CERO THERAPEUTICS HOLDINGS, INC.

    Non small cell lung cancer

    phase 3 small molecule active

    1 trial

  21. YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion., YERVOY 5 mg/ml concentrate for solution for infusion, Irinotecan Bendalis 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, FLUOROURACIL, OPDIVO 10 mg/mL concentrate for solution for infusion., Avastin 25 mg/ml concentrate for solution for infusion, DISODIUM FOLINATE

    Bristol-Myers Squibb Australia Pty Ltd

    Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient Metastatic Colorectal Cancer (dMMR)

    phase 3 small molecule active

    1 trial

  22. YESCARTA 0.4 – 2 x 10e8 cells dispersion for infusion, Revlimid 20 mg hard capsules, Bendamustine 100mg Powder for Concentrate for Solution for Infusion, Vincristine Sulfate 1 mg/ml Solution for Injection or Infusion, Doxorubicin Teva 2 mg/ml Concentrate for Solution for Infusion, Endoxana Injection 1000 mg Powder for Solution for Injection, Prednisolone 5 mg Soluble Tablets, MabThera 500 mg concentrate for solution for infusion

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory Follicular Lymphoma

    phase 3 small molecule active

    1 trial

  23. YF-17D

    Takeda

    Dengue

    phase 3 mab completed

    1 trial

  24. YTB323, TISAGENLECLEUCEL, PHE885

    Novartis Pharmaceuticals

    All patients who have been treated with Novartis or Penn CAR T-cell therapy for any indication

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources